Disposition of 33457 shares by Brian Crum of Lexicon Pharmaceuticals subject to Rule 16b-3
| LXRX Stock | USD 0.82 0.01 1.20% |
Slightly above 62% of Lexicon Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Lexicon Pharmaceuticals suggests that many traders are alarmed. Lexicon Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Lexicon Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Lexicon |
Filed transaction by Lexicon Pharmaceuticals Officer Svp, General Counsel Secr.. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Lexicon Pharmaceuticals Fundamental Analysis
We analyze Lexicon Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Lexicon Pharmaceuticals is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Lexicon Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lexicon Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Lexicon Pharmaceuticals Related Equities
| IBRX | Immunitybio | 9.81 | ||||
| ELEV | Elevation Oncology | 8.06 | ||||
| MCRB | Seres Therapeutics | 6.17 | ||||
| HEPA | Hepion Pharmaceuticals | 5.56 | ||||
| ENVB | Enveric Biosciences | 3.61 | ||||
| MREO | Mereo BioPharma | 2.09 | ||||
| HOOK | Hookipa Pharma | 0.50 | ||||
| DAWN | Day One | 1.51 | ||||
| ARDX | Ardelyx | 2.19 | ||||
| TERN | Terns Pharmaceuticals | 6.28 | ||||
| XFOR | X4 Pharmaceuticals | 10.81 | ||||
| BLRX | BioLineRx | 15.40 | ||||
| OCEA | Ocean Biomedical | 20.83 |
Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.